PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market

PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market is expected to grow to just over 8.5 million individuals by 2023: Radiant Insights, Inc Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023 Highlights Key Questions Answered - How large an impact will biosimilars have on the RA market? What do rheumatologists and key opinion leaders across the 10MM think about the evolving RA treatment landscape? - How is the uptake of JAK inhibitors expected to affect the global RA market? - Which novel biologics are the most promising? How are product launches expected to affect the antiTNFs? - According to KOLs, what are the most important unmet needs in RA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2023? - What governmental and industry developments are likely to affect sales of the top-selling RA drugs in the markets researched? Which is the largest growth market globally? Key Findings - Biosimilars are expected to change the landscape for RA and create pricing pressure in the RA market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.